# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activitie...
HC Wainwright & Co. analyst Edward White maintains Nyxoah (NASDAQ:NYXH) with a Buy and lowers the price target from $22 ...
Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development an...
Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering ProgramMont-Saint-Guibert, B...
Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development an...
HC Wainwright & Co. analyst Edward White reiterates Nyxoah (NASDAQ:NYXH) with a Buy and maintains $22 price target.
Oppenheimer analyst Suraj Kalia maintains Nyxoah (NASDAQ:NYXH) with a Outperform and lowers the price target from $20 to $15.
Cantor Fitzgerald analyst Ross Osborn maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $18 ...
Stifel analyst Jonathan Block maintains Nyxoah (NASDAQ:NYXH) with a Buy and maintains $27 price target.